Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brady

Showing results (451-460 of 627) with videos related to

Pageof 63
Sort By:
Nature Human Behaviour|June 27, 2022
Amplification in the evaluation of multiple emotional expressions over timeAmit Goldenberg, Jonas Schöne, Zi Huang, et al.
Nature Genetics|December 1, 1994
Mapping a gene for Noonan syndrome to the long arm of chromosome 12C R Jamieson, I van der Burgt, A F Brady, et al.
Gynecologic Oncology|May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyRobert S Mannel, Mark F Brady, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup studyGeorge A Omura, Mark F Brady, Katherine Y Look, et al.
Journal of Medical Genetics|July 16, 2021
Results from London Regional Clinical Genetics services over a 5-year period on germline <i>TP53</i> testing in women diagnosed with breast cancer at <30 yearsAlice Garrett, Sabrina Talukdar, Louise Izatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Cancer Research|March 1, 1991
Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallyl sulfideJ Y Hong, T Smith, M J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfaR J Harte, J C Matthews, S M O'Reilly, et al.
Pageof 63

Showing results (451-460 of 627) with videos related to

Sort By:
Pageof 63
Nature Human Behaviour|June 27, 2022
Amplification in the evaluation of multiple emotional expressions over timeAmit Goldenberg, Jonas Schöne, Zi Huang, et al.
Nature Genetics|December 1, 1994
Mapping a gene for Noonan syndrome to the long arm of chromosome 12C R Jamieson, I van der Burgt, A F Brady, et al.
Gynecologic Oncology|May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyRobert S Mannel, Mark F Brady, Elise C Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2003
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup studyGeorge A Omura, Mark F Brady, Katherine Y Look, et al.
Journal of Medical Genetics|July 16, 2021
Results from London Regional Clinical Genetics services over a 5-year period on germline <i>TP53</i> testing in women diagnosed with breast cancer at <30 yearsAlice Garrett, Sabrina Talukdar, Louise Izatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Cancer Research|March 1, 1991
Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallyl sulfideJ Y Hong, T Smith, M J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfaR J Harte, J C Matthews, S M O'Reilly, et al.
Pageof 63